Physician profile
Vidhya Illuri
NPI 1538480926
$3,644.15
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,276 · 2020: $324 · 2021: $774 · 2022: $132 · 2023: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $138.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Minimed, INC. | $2,393.86 | 2019-2020 | |
| Ibsa Pharma INC. | $750.00 | 2021 | |
| Dexcom, INC. | $273.91 | 2019-2023 | Dexcom G7 Gss (161) |
| Cequr Corporation | $118.43 | 2022 | |
| Novo Nordisk INC | $62.74 | 2019 | |
| Abbott Laboratories | $26.91 | 2022-2023 | Freestyle Libre 3 |
| Nevro Corp. | $18.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vidhya Illuri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.